# PrE0807 (NCT03532451)

> Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

No report yet. It can be ordered.

- Drugs tested: nivolumab plus lirilumab; nivolumab
- Indication: cisplatin-ineligible muscle-invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03532451
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: PrECOG, LLC.
- Conditions: Bladder Cancer
- Interventions: Nivolumab; Nivolumab/Lirilumab
- Enrollment: 43
- Primary outcome: Grade 3 or Higher Treatment Related Adverse Events as Assessed by CTCAE V5.0

## Indexed commentary on PrE0807 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=pre0807-nct03532451